vs
Side-by-side financial comparison of AMREP CORP. (AXR) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $14.6M, roughly 1.5× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs 7.2%, a 14.4% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 93.8%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -13.6%).
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
AXR vs CUE — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $21.9M |
| Net Profit | $3.1M | $1.6M |
| Gross Margin | — | — |
| Operating Margin | 20.6% | 9.0% |
| Net Margin | 21.6% | 7.2% |
| Revenue YoY | 93.8% | 1292.3% |
| Net Profit YoY | 338.9% | 116.7% |
| EPS (diluted) | $0.58 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | $21.9M | ||
| Q3 25 | $17.9M | $2.1M | ||
| Q2 25 | $11.2M | $3.0M | ||
| Q1 25 | $7.5M | $421.0K | ||
| Q4 24 | $11.9M | $1.6M | ||
| Q3 24 | $19.1M | $3.3M | ||
| Q2 24 | $19.5M | $2.7M |
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | $1.6M | ||
| Q3 25 | $4.7M | $-7.4M | ||
| Q2 25 | $3.9M | $-8.5M | ||
| Q1 25 | $717.0K | $-12.3M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | $-8.7M | ||
| Q2 24 | $4.1M | $-10.2M |
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | 9.0% | ||
| Q3 25 | 34.4% | -353.4% | ||
| Q2 25 | 31.7% | -292.3% | ||
| Q1 25 | 5.7% | -2921.4% | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 26.1% | -264.2% | ||
| Q2 24 | 23.9% | -390.6% |
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | 7.2% | ||
| Q3 25 | 26.3% | -346.6% | ||
| Q2 25 | 34.8% | -287.1% | ||
| Q1 25 | 9.5% | -2911.4% | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 21.3% | -259.6% | ||
| Q2 24 | 21.2% | -382.7% |
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | $0.05 | ||
| Q3 25 | $0.87 | $-0.07 | ||
| Q2 25 | $0.73 | $-0.09 | ||
| Q1 25 | $0.13 | $-0.17 | ||
| Q4 24 | $0.75 | — | ||
| Q3 24 | $0.76 | $-0.17 | ||
| Q2 24 | $0.77 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0M | $27.1M |
| Total DebtLower is stronger | $21.0K | — |
| Stockholders' EquityBook value | $139.4M | $26.4M |
| Total Assets | $143.9M | $42.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | $27.1M | ||
| Q3 25 | $48.9M | $11.7M | ||
| Q2 25 | $39.5M | $27.5M | ||
| Q1 25 | $36.9M | $13.1M | ||
| Q4 24 | $40.1M | $22.5M | ||
| Q3 24 | $40.4M | $32.4M | ||
| Q2 24 | $29.7M | $30.0M |
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | $1.0M | ||
| Q2 24 | $35.0K | $2.0M |
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | $26.4M | ||
| Q3 25 | $134.7M | $13.2M | ||
| Q2 25 | $130.0M | $18.2M | ||
| Q1 25 | $126.0M | $6.6M | ||
| Q4 24 | $125.1M | $17.5M | ||
| Q3 24 | $122.2M | $25.4M | ||
| Q2 24 | $118.0M | $21.6M |
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | $42.2M | ||
| Q3 25 | $140.7M | $31.6M | ||
| Q2 25 | $133.8M | $40.7M | ||
| Q1 25 | $128.9M | $22.3M | ||
| Q4 24 | $129.1M | $32.2M | ||
| Q3 24 | $127.0M | $44.8M | ||
| Q2 24 | $122.8M | $42.3M |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | 0.04× | ||
| Q2 24 | 0.00× | 0.09× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.4M | $-1.1M |
| Free Cash FlowOCF − Capex | $5.4M | — |
| FCF MarginFCF / Revenue | 37.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.72× | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $20.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | $-1.1M | ||
| Q3 25 | $9.5M | $-9.0M | ||
| Q2 25 | $10.2M | $-3.4M | ||
| Q1 25 | $-3.2M | $-8.2M | ||
| Q4 24 | $-182.0K | $-36.3M | ||
| Q3 24 | $10.7M | $-7.5M | ||
| Q2 24 | $10.7M | $-10.0M |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.7M | $-3.4M | ||
| Q1 25 | $-3.3M | $-8.3M | ||
| Q4 24 | $-268.0K | $-36.4M | ||
| Q3 24 | $10.7M | $-7.5M | ||
| Q2 24 | $10.3M | $-10.0M |
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 86.4% | -116.5% | ||
| Q1 25 | -43.4% | -1976.7% | ||
| Q4 24 | -2.3% | -2309.3% | ||
| Q3 24 | 55.8% | -225.7% | ||
| Q2 24 | 52.5% | -376.2% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 5.2% | 0.9% | ||
| Q1 25 | 0.3% | 35.6% | ||
| Q4 24 | 0.7% | 4.2% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 2.3% | 0.4% |
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | -0.68× | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXR
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
